S. Vieillot, D. Pouessel, N. M. de Champfleur and C. Becht, S. Culine, “Reversible Posterior Leukoencephalopathy Syn- drome after Carboplatin Therapy,” Annals of Oncology, Vol. 18, No. 3, 2007, pp. 608-609.
-
TITLE:
Cisplatin-Induced Posterior Reversible Encephalopathy Syndrome—Brief Report and Review of the Literature
AUTHORS:
Limor Amit, Irit Ben-Aharon, Thomas Tichler, Edna Inbar, Aaron Sulkes, Salomon M. Stemmer
KEYWORDS:
PRES; RPLS; Encephalopathy; Cisplatin; Hypertension
JOURNAL NAME:
Journal of Behavioral and Brain Science,
Vol.2 No.1,
February
29,
2012
ABSTRACT: Cisplatin is one of the most broadly used chemotherapeutic agents. Several central nervous system toxicities have been attributed to this agent, among which is a rare clinicoradiological condition referred to as posterior reversible leukoen-cephalopathy syndrome (PRES) or reversible posterior leukoencephalopathy syndrome (RPLS). PRES is characterized by subacute onset of headache, visual disturbances, confusion, seizures and rarely, coma. This usually reversible syn-drome was associated in the past mainly with hypertension. Several reports have associated the syndrome with several immunosuppressive and chemotherapeutic agents suggesting a disruption of the blood brain barrier due to direct damage to the endothelium and vasogenic edema. This syndrome is readily diagnosed with Computed Tomography (CT) or Magnetic resonance imaging (MRI) studies and quick withdrawal of the causative agent in conjunction with supportive care including rapid hypertension control and reduction of elevated intracranial pressure when needed, usually reverse the neurological symptoms with minimal or even no sequela within several days. In this brief report and review of the literature we describe two cases of PRES in two female patients that occurred a few days after receiving Cisplatin-based chemotherapy. We discuss the clinical presentation, diagnosis and treatment of this syndrome by reviewing the literature. The escalating number of clinical reports of PRES merit further studies of the mechanism of toxicity, appropriate treatment and awareness of physicians to this life threatening entity
Related Articles:
Late and Reversible Kidney-Lung Failure after Intra-Bladder BCG Therapy
Olivier Mat, Rim Kada, Patrick Philippart, Quentin Mat, Steffy Larroze, Myriam Remmelink, Selda Aydin, Vincent Colombie
DOI:
10.4236/ojneph.2013.33022
3,236 Downloads 5,075 Views Citations
Pub. Date:
September
9,
2013
Meta-Analysis to Determine the Diagnostic Value of 2-18Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Assessing Residual Tumors after Systemic Therapy for Metastatic Seminoma
Johannes Mueller, Thomas Schnoeller, Friedemann Zengerling, Sandra Waalkes, Andreas Al Ghazal, Florian Jentzmik, Mark Schrader, Andres Jan Schrader
DOI:
10.4236/oju.2011.13011
2,612 Downloads 5,171 Views Citations
Pub. Date:
August
9,
2011
